Proposed Issue of Securities — Appendix 3B

Imagion Biosystems has announced a Proposed Issue of Securities. Read the announcement.


IBX Raises $6M in Placement

Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…


Trading Halt

The securities of Imagion Biosystems will be placed in trading halt the request of IBX, pending it releasing an announcement. Read the ASX announcement and the…


Statement Pursuant to Listing Rule 4.7C.3

Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company…


Appendix C and Quarterly Activity Report

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3…


Quarterly Activity Report and Appendix C

Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…


Appendix 3Y — Change of Director's Interest Notice

Imagion Biosystems gave ASX information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Read…


Appendix 2A — Fully Paid Ordinary Shares

Imagion Biosystems has submitted "Appendix 2A — Application for quotation of +securities." Read Appendix 2A.


Vesting of Performance Rights

Imagion Biosystems has advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO Bob Proulx today,…


Notice Pursuant to Section 708(5)(e) of the Corporations Act 2001

Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of…